escitalopram teva
teva pharma b.v. - escitalopramas - plėvele dengtos tabletės - 20 mg; 10 mg - escitalopram
ellaone
laboratoire hra pharma - ulipristalas - kontracepcija, postcoital - lytiniai hormonai ir moduliatoriai lytinių organų sistema, , skubios pagalbos kontraceptikai. - neatidėliotinos kontracepcijos priemonės per 120 valandų (penkias dienas) nuo neapsaugoto lytinio akto ar kontracepcijos nepakankamumo.
quetiapine teva
teva pharma b.v. - kvetiapinas - plėvele dengtos tabletės - 300 mg; 200 mg; 25 mg - quetiapine
atorvastatin teva
teva pharma b.v. - atorvastatinas - plėvele dengtos tabletės - 80 mg; 40 mg; 20 mg; 10 mg - atorvastatin
quinapril-teva
teva pharma b.v. - kvinaprilis - plėvele dengtos tabletės - 20 mg; 10 mg; 40 mg - quinapril
sertraline-teva
teva pharma b.v. - sertralinas - plėvele dengtos tabletės - 50 mg - sertraline
amlodipine teva
teva pharma b.v. - amlodipinas - tabletės - 10 mg; 5 mg - amlodipine
finasteride teva
teva pharma b.v. - finasteridas - plėvele dengtos tabletės - 5 mg - finasteride
ajax disinfectant without bleach.
colgate-palmolive (poland) sp. z o.o., wybrzeze gdynskie 6d, pl-01531 warszawa (lenkija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.65% , veiklioji - maisto ir pašarų sritis
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūties navikai - antinavikiniai vaistai - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.